{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:05:40Z","timestamp":1740128740202,"version":"3.37.3"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"United States Government"},{"DOI":"10.13039\/100012737","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017443","name":"Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense","doi-asserted-by":"publisher","award":["W911QY-21-9-0001"],"award-info":[{"award-number":["W911QY-21-9-0001"]}],"id":[{"id":"10.13039\/100017443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We report spike protein-based lineage and AZD7442 (tixagevimab\/cilgavimab) neutralizing activity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants identified from breakthrough infections in the PROVENT preexposure prophylaxis trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Variants identified from PROVENT participants with reverse-transcription polymerase chain reaction-positive symptomatic illness were phenotypically assessed to determine neutralization susceptibility of variant-specific pseudotyped virus-like particles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At completion of 6 months' follow-up, no AZD7442-resistant variants were observed in breakthrough coronavirus disease 2019 (COVID-19) cases. SARS-CoV-2 neutralizing antibody titers were similar in breakthrough and nonbreakthrough cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Symptomatic COVID-19 breakthrough cases in PROVENT were not due to resistance-associated substitutions in AZD7442 binding sites or lack of AZD7442 exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT04625725.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad210","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T16:57:54Z","timestamp":1686329874000},"page":"1055-1059","source":"Crossref","is-referenced-by-count":1,"title":["Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab\/Cilgavimab) Resistant Variants"],"prefix":"10.1093","volume":"228","author":[{"given":"Kevin M","family":"Tuffy","sequence":"first","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar","family":"Ahani","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia A","family":"Aksyuk","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles","family":"Avila","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Brady","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo H","family":"Kijak","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Koh","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron J","family":"Levin","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine , Aurora, Colorado , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany L","family":"Roe","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolette","family":"Schuko","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Thissen","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Cambridge , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ustianowski","sequence":"additional","affiliation":[{"name":"North Manchester General Hospital , Manchester , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Discovery Sciences, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J","family":"Kelly","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Streicher","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca , Gaithersburg, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"2023101809351360700_jiad210-B1","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"2023101809351360700_jiad210-B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","article-title":"Omicron sublineage BQ.1.1 resistance to monoclonal antibodies","volume":"23","author":"Arora","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2023101809351360700_jiad210-B3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023101809351360700_jiad210-B4","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S1473-3099(22)00694-6","article-title":"Resistance of SARS-CoV-2 Omicron subvariant BA.4.6 to antibody neutralisation","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023101809351360700_jiad210-B5","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"2023101809351360700_jiad210-B6","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/cid\/ciac625","article-title":"Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality","volume":"76","author":"Kertes","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101809351360700_jiad210-B7","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"key":"2023101809351360700_jiad210-B8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12864-022-08358-2","article-title":"Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences","volume":"23","author":"O'Toole","year":"2022","journal-title":"BMC Genom"},{"key":"2023101809351360700_jiad210-B9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"2023101809351360700_jiad210-B10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023101809351360700_jiad210-B11","doi-asserted-by":"crossref","first-page":"103651","DOI":"10.1016\/j.ebiom.2021.103651","article-title":"Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis","volume":"73","author":"Maas","year":"2021","journal-title":"EBioMedicine"},{"key":"2023101809351360700_jiad210-B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"2023101809351360700_jiad210-B13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1126\/science.add2897","article-title":"T cell immunity to COVID-19 vaccines","volume":"377","author":"Wherry","year":"2022","journal-title":"Science"},{"key":"2023101809351360700_jiad210-B14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad210\/50659776\/jiad210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/8\/1055\/52209978\/jiad210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/8\/1055\/52209978\/jiad210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T09:36:35Z","timestamp":1697621795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/8\/1055\/7191107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,6]]},"published-print":{"date-parts":[[2023,10,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad210","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2023,10,15]]},"published":{"date-parts":[[2023,6,6]]}}}